Breaking News Instant updates and real-time market news.

NVS

Novartis

$85.88

1.1 (1.30%)

, LPCN

Lipocine

$1.63

0.07 (4.49%)

04:55
01/06/19
01/06
04:55
01/06/19
04:55

Focus Medical Communications to hold a conference

NASH-TAG Conference 2019 will be held in Park City, Utah on January 3-6.

NVS

Novartis

$85.88

1.1 (1.30%)

LPCN

Lipocine

$1.63

0.07 (4.49%)

NVO

Novo Nordisk

$47.35

0.13 (0.28%)

  • 06

    Jan

  • 06

    Jan

  • 06

    Jan

  • 06

    Jan

  • 07

    Jan

  • 07

    Jan

NVS Novartis
$85.88

1.1 (1.30%)

12/11/18
JEFF
12/11/18
INITIATION
Target $105
JEFF
Buy
Novartis assumed with a Buy at Jefferies
Jefferies analyst Peter Welford assumed coverage of GNovartis with a Buy rating and $105 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum."
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Underweight
Novartis downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company's pipeline and believes the shares are close to fair value.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
LPCN Lipocine
$1.63

0.07 (4.49%)

03/29/18
GHSC
03/29/18
INITIATION
Target $10
GHSC
Buy
Lipocine initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Lipocine with a Buy and $10 price target. The analyst believes investors have given up on approval for Tlando given the complete response letter in 2016, the negative FDA AdCom, and current valuation. Davis does not expect FDA approval on the final FDA May 8 PDUFA, but thinks the agency may ask for ambulatory blood pressure study and study comparing "serum" testosterone to "plasma" testosterone in patients before and after dosing. If so, shares should react favorably and if the studies are positive, shares could react significantly.
02/27/18
EAMC
02/27/18
UPGRADE
EAMC
Buy
Lipocine upgraded to Buy from Hold at Empire
Empire analyst Cathy Reese upgraded Lipocine to Buy with a $21 price target, shares currently trade at $1.31, saying there is a high probability Tlando will gain approval, whether its on the May 8 PDUFA or once the once the blood pressure and collection test tube clinical data is reviewed sometime in 2018.
01/12/18
HCWC
01/12/18
NO CHANGE
Target $3
HCWC
Buy
Lipocine price target lowered to $3 from $10 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for Lipocine to $3 saying the company is a "show me" story following the negative Tlando FDA panel vote. The analyst keeps a Buy rating on the shares.
01/11/18
LTCO
01/11/18
NO CHANGE
Target $11
LTCO
Buy
Lipocine price target lowered to $11 from $15 at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan cut his price target for Lipocine to $11 after an FDA committee voted 13 to 6 that the risk/benefit profile of Tlando is not currently supportive of approval for the treatment of hypogonadism. The analyst believes Tlando continues to represent an approvable product and that the blood pressure question can be addressed via a relatively a "relatively straightforward" study. Kaplan cites the likelihood of a complete response letter from the FDA for his target reduction but keeps a Buy rating on Lipocine shares.
NVO Novo Nordisk
$47.35

0.13 (0.28%)

12/11/18
JEFF
12/11/18
INITIATION
JEFF
Hold
Novo Nordisk assumed with a Hold at Jefferies
Jefferies analyst Peter Welford assumed coverage of Novo Nordisk with a Buy rating and DKK 285 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum." He calls Novo his least preferred stock in the group.
01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
11/26/18
PART
11/26/18
UPGRADE
PART
Buy
Novo Nordisk upgraded to Buy from Hold at Pareto
11/19/18
JPMS
11/19/18
UPGRADE
JPMS
Overweight
Novo Nordisk upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser upgraded Novo Nordisk to Overweight and raised his price target for the shares to 340 kroner from 290 kroner. The analyst sees the company's growth strengthening through 2019.

TODAY'S FREE FLY STORIES

AMRN

Amarin

$22.74

0.11 (0.49%)

, MDCO

The Medicines Co.

$70.17

11.51 (19.62%)

07:41
11/20/19
11/20
07:41
11/20/19
07:41
Recommendations
Citi prefers Amarin shares to The Medicines Co. after this week's divergence »

Amarin (AMRN) shares this…

AMRN

Amarin

$22.74

0.11 (0.49%)

MDCO

The Medicines Co.

$70.17

11.51 (19.62%)

NVS

Novartis

$90.42

0.14 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 28

    Dec

FTDR

Frontdoor

$45.68

1.26 (2.84%)

07:41
11/20/19
11/20
07:41
11/20/19
07:41
Conference/Events
Frontdoor management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

RCI

Rogers Communications

$47.86

(0.00%)

, AMZN

Amazon.com

$1,752.17

-0.53 (-0.03%)

07:40
11/20/19
11/20
07:40
11/20/19
07:40
Hot Stocks
Rogers announces availability of Amazon Prime Video on Ignite TV »

Rogers (RCI) announced…

RCI

Rogers Communications

$47.86

(0.00%)

AMZN

Amazon.com

$1,752.17

-0.53 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

RJF

Raymond James

$89.25

-0.06 (-0.07%)

07:40
11/20/19
11/20
07:40
11/20/19
07:40
Initiation
Raymond James initiated  »

Raymond James initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
11/20/19
11/20
07:40
11/20/19
07:40
General news
Treasury Market Outlook: yields continued to fall overnight »

Treasury Market Outlook:…

KSS

Kohl's

$47.01

-11.38 (-19.49%)

07:39
11/20/19
11/20
07:39
11/20/19
07:39
Recommendations
Kohl's analyst commentary  »

Kohl's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FRPT

Freshpet

$54.37

-0.1 (-0.18%)

07:39
11/20/19
11/20
07:39
11/20/19
07:39
Conference/Events
Freshpet management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

HLI

Houlihan Lokey

$47.69

0.18 (0.38%)

07:38
11/20/19
11/20
07:38
11/20/19
07:38
Initiation
Houlihan Lokey initiated  »

Houlihan Lokey initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLXN

Flexion

$16.43

0.335 (2.08%)

07:38
11/20/19
11/20
07:38
11/20/19
07:38
Conference/Events
Flexion management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

HOLX

Hologic

$47.17

0.43 (0.92%)

07:37
11/20/19
11/20
07:37
11/20/19
07:37
Hot Stocks
Hologic to sell its Cynosure business for $205M, to enter new $205M ASR »

Hologic announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTOO

T2 Biosystems

$1.82

0.07 (4.00%)

07:37
11/20/19
11/20
07:37
11/20/19
07:37
Hot Stocks
T2 Biosystems announces granting of CE Mark for T2Resistance Panel »

T2 Biosystems and CARB-X…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$359.52

9.53 (2.72%)

07:37
11/20/19
11/20
07:37
11/20/19
07:37
Recommendations
Tesla analyst commentary  »

Tesla's base…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAZ

Lazard

$37.61

0.12 (0.32%)

07:36
11/20/19
11/20
07:36
11/20/19
07:36
Initiation
Lazard initiated  »

Lazard initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHC

A.H. Belo

$3.15

0.03 (0.96%)

07:35
11/20/19
11/20
07:35
11/20/19
07:35
Hot Stocks
A.H. Belo announces restatement, receives NYSE notice on late 10-Q filing »

A. H. Belo Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBA

Pembina Pipeline

$36.21

0.04 (0.11%)

07:34
11/20/19
11/20
07:34
11/20/19
07:34
Hot Stocks
Pembina Pipeline's acquisition of Kinder Morgan Canada approved by CCB »

Pembina Pipeline and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVR

Evercore Partners

$76.43

0.64 (0.84%)

07:34
11/20/19
11/20
07:34
11/20/19
07:34
Initiation
Evercore Partners initiated  »

Evercore Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VVUS

VIVUS

$2.84

0.09 (3.27%)

07:33
11/20/19
11/20
07:33
11/20/19
07:33
Hot Stocks
VIVUS announces results of clinical study of Qysmia in patients with BED, BN »

VIVUS announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WWD

Woodward

$115.83

2.19 (1.93%)

07:32
11/20/19
11/20
07:32
11/20/19
07:32
Downgrade
Woodward rating change  »

Woodward downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

HOLX

Hologic

$47.17

0.43 (0.92%)

07:32
11/20/19
11/20
07:32
11/20/19
07:32
Hot Stocks
Clayton, Dubilier & Rice to acquire Cynosure from Hologic »

Clayton, Dubilier &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAVA

Endava

$44.07

-0.05 (-0.11%)

07:31
11/20/19
11/20
07:31
11/20/19
07:31
Recommendations
Endava analyst commentary  »

Endava price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

MYOS

MYOS

$1.49

(0.00%)

07:31
11/20/19
11/20
07:31
11/20/19
07:31
Hot Stocks
MYOS' Fortetropin shows muscle increase in accepted clinical trial presentation »

MYOS RENS, owner of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XCUR

Exicure

$2.60

0.13 (5.26%)

07:31
11/20/19
11/20
07:31
11/20/19
07:31
Initiation
Exicure initiated  »

Guggenheim starts Exicure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$6.08

-1.9 (-23.81%)

07:30
11/20/19
11/20
07:30
11/20/19
07:30
Upgrade
Intelsat rating change  »

Intelsat upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MOGA

Moog Inc

$0.00

(0.00%)

, MOG

Moog Inc

$0.00

(0.00%)

07:30
11/20/19
11/20
07:30
11/20/19
07:30
Hot Stocks
Moog awarded $400M F-35 actuation system contracts from Lockheed Martin »

Moog (MOG) announced that…

MOGA

Moog Inc

$0.00

(0.00%)

MOG

Moog Inc

$0.00

(0.00%)

MOG.A

Moog

$88.00

0.39 (0.45%)

MOG.B

Moog

$81.29

(0.00%)

LMT

Lockheed Martin

$390.66

-2.07 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$83.45

-1.32 (-1.56%)

, JWN

Nordstrom

$35.51

-2.37 (-6.26%)

07:30
11/20/19
11/20
07:30
11/20/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

PM

Philip Morris

$83.45

-1.32 (-1.56%)

JWN

Nordstrom

$35.51

-2.37 (-6.26%)

FNV

Franco-Nevada

$98.66

-0.36 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.